Eric joined EyeBio in 2023 as Senior Vice President of Biology. He is responsible for pre-clinical research and development as well as pipeline expansion.
Prior to EyeBio, Eric was an Assistant Professor of Ophthalmology at the Schepens Eye Research Institute of Mass Eye and Ear and Harvard Medical School, where his research has focused on the biology of vascular endothelial growth factor (VEGF) and its role in the pathogenesis of neuro-vascular diseases of the eye and developing novel therapeutics for these diseases.
Previously, Eric was involved in the discovery of therapeutic targets and drug development for age-related macular degeneration (AMD) and diabetic retinopathy as a lecturer associated with the late Professor David Shima at UCL Institute of Ophthalmology in London through research collaborations with GSK. Before returning to academia, Eric was a Senior Scientist and later Associate Director of Drug Discovery at Eyetech Pharmaceuticals.
Eric received his B.A. in Biology and B.A./M.A. in Biotechnology from Boston University and his Ph.D. in Cell and Developmental Biology from Harvard Medical School. Eric completed his post-doctoral research fellowship in vascular biology at the Schepens Eye Research Institute.
